Juvenile idiopathic arthritis (JIA) and pediatric joint disorders
Clinical trials in pediatric rheumatic diseases present scientific and operational challenges. Yet, few opportunities exist to expose investigators to regulatory considerations around these complex pediatric research trials. The ACR, in collaboration with the Food and Drug Administration, present this session on regulatory and clinical trial design considerations in pediatric rheumatology. This interactive talk will address unique aspects of leveraging adult data and provide an overview of innovative trial design. The session will allow for an open dialogue between regulators and academic researchers to evaluate and discuss paths to advance the development of therapies for pediatric rheumatic diseases.